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Abstract The role of heterotrimeric G proteins in T-cell 
activation is poorly understood. Here we show that in normal, 
mature human T-cells, expression of G(Xi6, the 43 kDa a subunit 
of G16, varies widely, depending on T-cell activation status. 
Quiescent blood lymphocytes strongly up-regulate Ga i 6 after 
Leuco A stimulation: protein expression of G(Xi6 is maximal at 
day 4, then decreases. Consistently, in human T-cell clones, 
expression of Ga i 6 is high in the first week following activation 
and decreases rapidly within the second week. In addition, 
permanent disruption of regulated Ga16 expression in Jurkat T-
cells by stable overexpression of 43 kDa Gcti6 inhibited Leuco A-
induced interleukin-2 production, CD69 up-regulation and cell 
apoptosis (by 58%, 46% and 74%, respectively), suggesting that 
coordinate regulation of Gcti6 expression is necessary for optimal 
activation-induced T-cell responses, and that Ga16 proteins may 
be involved in the negative regulation of TCR signalling. 
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1. Introduction 
Recent studies have suggested that heterotrimeric GTP-
binding proteins (G proteins) may play a role in the regulation 
of T-lymphocyte functions [1]. Abnormal thymocyte migra-
tion and maturation was reported in transgenic mice express-
ing in T-cells the catalytic subunit of pertussis toxin [2,3], a 
toxin which inhibits the function of G; proteins; transgenic 
mice deficient in the a subunit of G;2 proteins also have func-
tionally abnormal T-cells [4,5]. The G proteins Gq and Gn 
may also play a role in the regulation of TCR signalling [6,7]. 
Hence, studies of G protein expression in human T-lympho-
cytes at different states of activation and differentiation might 
help understand G protein functions in T-cell regulation. The 
G protein family includes 20 distinct G proteins, made of a 
subunits and fty complexes [8-10] and divided into four major 
sub-families (Gs, G;, Gq, G]2) based on the degree of amino 
acid identity of their a subunits. In the Gq family, Goti6, the a 
subunit of Gig, was originally described as a 43 kDa protein 
expressed specifically in hemopoietic cells [11]. Because most 
studies of Got subunits in blood cells were carried out on 
mRNAs [11-14], little is known of G protein expression in 
human blood T-lymphocytes. Gs and Gi2 are ubiquitous; 
Gq and Gn RNAs were found in human thymocytes [14]; 
in human lymphoid cell lines, Gq proteins, but not Gn pro-
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teins, were detected [12]. Goti6 mRNA was found in immature 
human lymphoid cells of B lineage [13], in two T-cell lines, 
MOLT and CEM, and in human thymocytes [11,14]; in hu-
man T-lymphocytes, protein expression of Gccig has been de-
scribed only in tonsil T-cells [15]. Expression of Gie and G12 
proteins varies according to cell lineage and/or degree of dif-
ferentiation in myeloid cells [11,16], but nothing is known of 
G12 or Gi6 protein expression during differentiation and acti-
vation of normal human T-cells. In this study, we used im-
munoblotting techniques with polyclonal antibodies specific 
for Ga subunits to screen human peripheral blood lympho-
cytes (PBL) and various T-cell clones characterized by their T-
cell receptor (TCR) chain rearrangements, CD4/CD8 expres-
sion, or Thl or Th2 cytokine profile [17,18]. 
2. Materials and methods 
2.1. Peripheral blood lymphocyte (PBL) preparation and cultures 
PBL were obtained from fresh heparinized blood of healthy donors. 
After platelet removal, > 95% pure lymphocyte preparations (PBL), 
consisting of at least 70% T-lymphocytes, were obtained by separation 
of mononuclear cells by Ficoll-Hypaque gradient centrifugation fol-
lowed by two cycles of adherence to plastic to remove monocytes [16]. 
PBL were stimulated with 0.5 ug/ml Leuco A (leucoagglutinin A, also 
called PHA-L, Sigma, St. Louis, MO) and 30 ng/ml of recombinant 
human interleukin-2 (rh IL-2, Cetus, USA) and grown at a concen-
tration of 5X105 cells/ml in RPMI plus 10% fetal calf serum (FCS) 
for up to 6 days. After two washes with PBS pH 7.5, cell pellets were 
kept frozen at —80°C until membrane preparation. 
2.2. T-cell clone cultures 
The human T-cell clones used in this study, provided by Drs. Henri 
Vie and Marc Bonneville (INSERM U463, Nantes, France), have 
been previously described [17,18]. Clones were grown in RPMI plus 
10% FCS and rh IL-2 (30 ng/ml). After co-stimulation with Leuco A 
(1 ng/ml) and 35 Gy irradiated accessory cells (EBV-transformed B-
cells and peripheral blood mononuclear cells) [17,18], clonal T-cells 
were grown in RPMI plus 10% FCS and rh IL-2 (30 ng/ml), for 7, 14, 
21 or 28 days. Cells were then washed twice with PBS pH 7; cell 
pellets were kept frozen at —80°C until membrane preparation. 
2.3. Jurkat cell transfection 
lurkat cells were grown in RPMI plus 10% FCS. Transfection was 
performed by electroporation at 270 V, 1500 uF, in 800 ul of RPMI in 
a 4 mm cuvette (Easyject), with pcDNA3 constructs (30 ug of line-
arized DNA per 5X 106 cells) containing sense or anti-sense cDNAs 
encoding human Gai6 [19]. Cells were allowed to recover in RPMI 
plus 10% FCS for 24 h, then selected with 750 ug/ml G418-sulfate for 
2 weeks. All the studies described below were carried out on pools of 
transfected, G418-sulfate-resistant cells. 
2.4. Protein analysis 
After thawing of frozen cell pellets, crude membranes were pre-
pared and protein concentration determined by the BCA method 
(Pierce), with BSA used as a standard, as previously described 
[16,20], Membrane proteins (10 ug or 20 ug) were resolved on 10% 
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Fig. 1. Expression of Ga subunits in human PBL and T-cell clones. Membrane proteins (10 |xg/lane, left panel; 20 |xg/lane, right panel) of PBL 
and T-cell clones characterized by TCR chain, CD4/CD8 expression (left panel) or cytokine profile (right panel) were resolved by SDS/10% 
PAGE and transferred to PVDF. Duplicate blots were incubated first with antiserum AR (Goti6), then with AS (Go^) or QL (Gaq /n), or with 
QE (GCX12) first, then AS (Ga;2) (left panel). Four clones (left panel) were tested on two different cell and membrane preparations (a, b). 
SDS-polyacrylamide gels and transferred onto polyvinylidene difluo-
ride (PVDF) membranes (Millipore). For each set of cell and mem-
brane preparations, two identical gels were loaded in order to obtain 
two identical blots. Immunoblotting was carried out with 0.2 iig/ml of 
affinity-purified antibodies: AS 7, specific for Go^ [21]; AR, directed 
against the last 10 C-terminal amino acids (ARYLDEINLL) of the a 
subunit of human Gi6 [16,21,22]; QL, specific for Ga q /n [23]; QE, 
specific for Gai 2 [16] or RM, specific for Gctj [22]. Antibody-antigen 
complexes were detected by enhanced chemiluminescence (ECL kit, 
Boehringer-Mannheim). Blots were exposed to RX Fuji films to vis-
ualize immunoreactive bands. For each blot, the complete procedure 
(incubation with primary and secondary antibodies, ECL revelation) 
was repeated twice using different affinity-purified antibodies, allowing 
screening of several G a proteins on the same membrane preparations. 
2.5. Cytokine production 
Culture supernatants were harvested 18 h after stimulation in trip-
licate of Jurkat cells with 0.5 ng/ml Leuco A, and kept at —80°C. IL-2 
secretion was assessed by ELISA using the IL-2 EASIA kit (Medge-
nix, France). 
2.6. Immunofluorescence studies 
Jurkat cells were harvested 18 h after Leuco A stimulation, fixed 
with 1% paraformaldehyde (PFA) and kept at 4°C until labelling. 
After two washes with PBS plus 1% BSA, cells were resuspended in 
25 ul of the same buffer containing a 1:25 dilution of phycoerythrin-
conjugated anti-CD69 antibody (Leu 23, Becton-Dickinson) for 30 
min at 4°C. Non-specific fluorescence was determined with isotype-
matched irrelevant antiserum. Cells were analyzed on a FACScan 
cytofluorometer (Becton-Dickinson). 
2.7. Detection of Leuco A-induced cell death 
Jurkat cells were stimulated in triplicate with Leuco A for 18 h. 
Apoptotic cells (defined as binding annexin V and excluding propidi-
um iodide) were labelled using an Annexin V-FITC kit (Boehringer-
Ingelheim, Germany) and analyzed on a FACScan cytofluorometer. 
3. Results and discussion 
3.1. Expression of Ga subunits in human T-cells 
Expression of G a subunits in human T-cell clones and in 
PBL of healthy donors is shown in Fig. 1. Expression of G(Xi2 
and Gocq/ii proteins was high in both PBL and T-cell clones, 
with only slight variations among clones. GCC12 proteins were 
not detected in PBL; in clones, there was some variability in 
G0C12 expression, but G0C12 protein levels were always very low 
in human T-cells. As in human myeloid cells [16], the anti-
Goiig A R antiserum recognized two proteins in human T-
cells: G0C16 (43 kDa) and another protein of apparent molec-
ular mass 46 kDa . These two proteins were also revealed by 
AS 339/3 [16,24], another antibody raised against the C-ter-
minal port ion of Gcci6 (data not shown). The levels of expres-
sion of both Goci6 and the 46 k D a protein were variable: PBL 
and CD8+ clones expressed bo th proteins at low levels; the 
CD4+ clone and two y8 T C R clones expressed Gcti6 at high 
levels, but only the C D 4 + clone also expressed the 46 k D a 
protein at high levels. In T h l and Th2 clones, expression of 43 
k D a Gaig proteins varied from very low (clones 14, 11, 21) to 
very high (clone D2) ; expression of the 46 k D a protein, also 
variable, was not detected in clones 14 and C14. Four clones 
(A17.10, A2.10, A18.1, G12) were tested twice, on different 
cell preparations (left panel); all expressed Goii6 and the 46 
k D a protein but at different levels on each preparation. In 
contrast, expression of GoCi2 and G a q / n , tested on the same 
blots, was identical in both membrane preparations. 
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Fig. 2. Expression of Gai 6 proteins in activated PBL. Leuco A/IL-
2-stimulated PBL were grown in vitro for the indicated times. Mem-
brane proteins (20 |ig/lane) were resolved by SDS/10% PAGE, 
transferred to PVDF, and blots were incubated first with AR 
(Ga16), then AS (Ga i2) antisera. This experiment was repeated three 
times, on different PBL and membrane preparations. 
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Fig. 3. Expression of Gaig proteins in activated human T-cell 
clones. Two Th2, CD4+ clones (Pll, P14), one Thl, CD4+ clone 
(HER1) and one CD8+ clone (A2.10, right panel) were subjected to 
co-stimulation with Leuco A, IL-2 and irradiated B-cells (see Sec-
tion 2) and grown in vitro for 1 month. Membrane proteins (20 |J,g/ 
lane) were resolved by SDS/10% PAGE, transferred to PVDF and 
blots were incubated with AR (Gai6), then RM (Gas) antisera. In 
clones Pll, P14 and HER1, the 46 kDa protein was not detected 
(left panel). 
3.2. Regulation of Ga^e protein expression during T-cell 
activation 
As shown in Fig. 1, protein expression of (43 kDa) Goti6 
was low in PBL, which are presumably quiescent, and in 
CD8+ clones, which have a low proliferation potential; in 
contrast, expression of Goci6 was high in CD4+ and y8 TCR 
clones, which tend to have a high proliferation potential, sug-
gesting that Gcti6 expression might be associated with T-cell 
activation or/and proliferation status. We then stimulated 
freshly isolated PBL with Leuco A and IL-2 and studied 
Goii6 expression (Fig. 2). Expression of Gai6 proteins was 
strongly increased at day 4 post stimulation, and started to 
decrease by day 6. Interestingly, expression of the 46 kDa 
protein also increased in activated PBL, with different kinetics 
since its expression was already maximal at 48 h, and returned 
to the pre-stimulation level at day 6. Four T-cell clones were 
subjected to Leuco A/IL-2 co-stimulation and tested for Ga,\§ 
expression in the following month (Fig. 3). Expression of 43 
kDa Goci6 was high during the first week post stimulation, 
decreased during the second week and was almost undetect-
able after 2 weeks. At day 21 and after, expression of the 46 
kDa protein was also reduced. 
Gcc;2 and G a q / n proteins have been reported to affect T-
cell activation or/and differentiation [4-7]. In T-cell clones, 
expression of neither Goc;2 and G a q / n (Fig. 1) nor Ga s 
(Fig. 3) was affected by activation or proliferation status. 
Similarly, no change in expression of Gofe (Fig. 2) was ob-
served in activated PBL. This, however, does not rule out that 
changes in the function of G^ or G q / n may occur during T-
cell activation. In contrast, expression of GtXi6 was positively 
correlated with the activated state of human T-cells. Such up-
regulation contrasts with the down-regulation of Goti6 ob-
served during granulocytic, erythrocytic and B-cell differentia-
tion [11,13,16]. Another finding of this study is the existence in 
T-cells of a 46 kDa protein, which, as in myeloid cells [16], is 
recognized by antibodies directed against the C-terminal por-
tion of Gcci6. Indeed, in a recent report by Grant et al. [15], 
anti-Gccis antibodies also recognized two proteins in T-cells 
from human tonsils and in Jurkat cells. Like GoCi6, this 46 
kDa protein is up- and down-regulated in activated T-cells. 
This would be consistent with the existence of a novel Goc 
subunit closely related to Gai6, as in the Gcc; family. As 
previous studies of Gcti6 in hemopoietic cells were carried 
out on mRNAs [11,13], mostly with RT-PCR techniques, a 
second Goci6 gene may have been missed. 
3.3. Disruption of the regulation of Gats protein expression 
with sense or anti-sense Gfiie constructs: effects on 
Leuco A-induced activation of Jurkat cells 
Up-regulation of Goci6 protein expression in activated T-
cells could be either a non-essential consequence of T-cell 
activation or an absolute requirement for efficient T-cell acti-
vation. To distinguish between these two possibilities, disrup-
tion of the regulation of Gcti6 protein expression in human 
PBL would be the ideal strategy. However, as PBL cannot 
readily be transfected, we used Jurkat, a human T-lymphoma 
cell line commonly used to study TCR-mediated activation. 
After TCR activation, Jurkat cells, like PBL, produce IL-2 
and up-regulate expression of CD69, a cell surface activation 
marker [25]. Unlike PBL, which proliferate within 5 days of 
TCR activation, Jurkat cells undergo apoptosis within 24 h 
[26]. In order to disrupt Goci6 expression, Jurkat cells were 
stably transfected with either sense or anti-sense pcDNA3 
constructs encoding human G a ^ ; the Goci6 cDNA cloned 
in the pcDNA3 constructs encodes 43 kDa Goti6 [11,19]. As 
shown in Fig. 4, in Jurkat cells as in lymphocytes, the AR 
antiserum recognizes 43 kDa Gai6 (weakly expressed in Jur-
kat cells) and a 46 kDa protein. Expression of 43 kDa Goci6 is 
clearly increased in Jurkat cells transfected with sense GtXi6 
and is below the detection level in cells transfected with anti-
sense Goci6. Studies of Goci6 protein expression during activa-
tion of Jurkat cells by Leuco A were not possible: indeed, 
activation-induced apoptosis occurs very rapidly in Jurkat 
cells, and Western blot studies show evidence of apoptosis-
related degradation of membrane proteins as early as 6 h post 
activation (data not shown). 
Responses of transfected Jurkat cells to Leuco A stimula-
tion (IL-2 production, up-regulation of CD69 expression, cell 
apoptosis) were studied (Fig. 5). In cells transfected with sense 
Gcci6, responses to Leuco A stimulation were strongly inhib-
ited. In these cells, CD69 expression was inhibited by 4(M-6%; 
only 21 ± 1% of sense Goii6-transfected cells expressed CD69 
(vs. 35 ± 2% of vector-transfected cells (Fig. 5A), a 40% inhib-
ition) with a mean intensity of fluorescence (MFI) reduced by 
46% (Fig. 5B), and IL-2 production was inhibited by 58% 
(Fig. 5C), compared to vector-transfected cells. Only 
6.0 ±0.1% of sense Goii6-transfected cells stimulated for 18 
h with 0.5 |xg/ml Leuco A underwent apoptosis (vs. 
22.7 ±1.7% of vector-transfected cells, a 74% inhibition) 
(Fig. 5D). Transfection with the anti-sense G(Xi6 construct 
had little effect on Jurkat cell responses to Leuco A stimula-
tion. In these cells, CD69 expression was not significantly 
affected: 31 ± 1 % of anti-sense Goci6-transfected cells ex-
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Fig. 4. Expression of Gaie in transfected Jurkat cells. Membranes 
(20 ug/lane) of Jurkat cells transfected with sense or anti-sense Goii6 
constructs were resolved by SDS/10% PAGE, transferred to PVDF 
and blots were incubated first with AR (Gai6), then AS (Gai2) anti-
sera. 
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Fig. 5. Response of sense or anti-sense Gai6-transfected Jurkat cells to Leuco A stimulation. 10
6 Jurkat cells transfected with vector alone, 
sense or anti-sense Gaig were stimulated with 0.5 u,g/ml Leuco A in 1 ml wells, in triplicate, for 18 h. Data are presented as means ±S.E.M.; 
*P < 0.05, Student's /-test (compared to vector-transfected cells). All experiments were repeated three times. CD69 expression, prior to and after 
Leuco A stimulation, and analyzed by FACScan after labelling of PFA-fixed cells with anti-CD69 antibodies, is presented as percentage of cells 
expressing CD69 (A) and as CD69 MFI of cells expressing CD69 (B); in the absence of stimulation, less than 2% of Jurkat cells (transfected 
or not) expressed CD69, with a M F K 12. IL-2 content was measured in culture supernatants by ELISA (C), and cell apoptosis, assessed by 
propidium iodide exclusion and annexin V binding, is presented as percentage of apoptotic cells after stimulation with 0.05, 0.10 or 0.50 |xg/ml 
Leuco A (D). 
pressed CD69 (vs. 35 ± 2% for vector-transfected cells, Fig. 
5A) with a M F I reduced by only 2 1 % (Fig. 5B); IL-2 produc-
tion was inhibited by 35% (Fig. 5C) and 14.9 ± 0.8% of anti-
sense Gai6-transfected cells stimulated with 0.5 |J,g/ml Leuco 
A underwent apoptosis (vs. 22.7 ± 1.7% of vector-transfected 
cells, a 34% inhibition) (Fig. 5C). Hence, inhibition of Jurkat 
cell responses to Leuco A activation was strong (40-74%) 
when overexpression of 43 k D a Goci6 was enforced, and 
weak ( < 35%o inhibition) when increases in 43 k D a Gocig ex-
pression were prevented by transfection with the anti-sense 
Goii6 construct. These observations suggest that sequential 
up- and down-regulation of G(Xi6 protein expression is neces-
sary for optimal T-cell response to activation. They also sug-
gest that Goii6 may negatively regulate T C R signalling, since 
maximal inhibition of Jurkat cell responses to activation was 
obtained in cells transfected with sense Gcci6. Indeed, survival 
of activated T-cells requires balancing of cell proliferation and 
apoptosis and adequate down-regulation of T C R signalling is 
essential to prevent uncontrolled, excessive apoptosis of acti-
vated T-cells. If Goci6 negatively regulates T C R signalling, 
Goii6 expression would logically return to low basal levels 
once T C R signalling is stopped: this is what was observed 
in PBL. According to this hypothesis, inhibition of activa-
tion-induced apoptosis and IL-2 production was not expected 
in Jurkat cells transfected with anti-sense Goti6. However, the 
inhibition observed was weak ( < 35%>) and might not be sig-
nificant. One should also take into account that the 46 k D a 
protein, the most abundant protein recognized by ant i -Gaie 
antibodies in Jurkat cells, remained expressed at high levels in 
anti-sense Goti6 cells (Fig. 4). Thus, cells may express enough 
functional Goii6 proteins to down-regulate activation signals 
in a manner similar to vector-transfected cells. Alternatively, 
if T C R signalling cannot be stopped appropriately in cells 
transfected with anti-sense Gdi6 , these cells may be in a (par-
tially) refractory state, and therefore less capable of respond-
ing to Leuco A stimulation. These hypotheses are currently 
being investigated. 
In conclusion, Goti6 proteins can be distinguished from 
other heterotrimeric G proteins by their specific and tightly 
regulated expression during activation of human T-cells. Fur-
thermore, this study provides evidence that the coordinated 
regulation of Goci6 expression observed in blood T-lympho-
cytes is required for optimal T-cell activation and suggests a 
role for Gcti6 proteins in the negative regulation of T C R 
signalling. 
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